Abstract 100P
Background
Intraarterial chemotherapy showed promising results in treatment of primary unresectable liver metastases of colorectal cancer. Moreover it also showed effectiveness in liver metastases resistant to standard intravenous / per os chemotherapy. Our aim was to assess whether drug combination influences outcomes.
Methods
Records of 96 patients with primary unresectable metastatic colorectal cancer (liver only) who received intraarterial 5-FU based chemotherapy in period from 2008 to 2020. We separated groups according to chemotherapy drugs: 5-FU monotherapy (Group A), FOLFOX (Group B) and FOLFIRI (Group C) accordingly. In the FOLFIRI group patients received Irinotecan intravenously.
Results
According to analyzed data in Group A there were 61 patients, in Group B 23 and in Group C 12 patients. Objective response was achieved in 51 patient (53.1%), 47.5% (n=29) in Group A, 47.8 (n=11) in Group B and 33.3% (n=4) in Group C. 41 patients (42.7%) undergone complete surgical resection of liver metastases, in 4 of them (9.7%) complete pathological response was achieved. Surgical morbidity and mortality rates were 7.3 (n=3) and 2.4 % (n=1) respectively. In those patients who didn’t undergo resection the main reasons were: not achieving criteria for resectability (16 patients) and comorbidities (4 patients).
Conclusions
Intraarterial chemotherapy for primary unresectable liver metastases remains a good option for this condition, but further bigger studies are needed to find the best scheme for this.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.